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Summary
Uveal melanoma represents 5% of all melanomas and the eye is the second most common site for primary melanoma 
after the skin. Delays or failure to make an accurate and early diagnosis may have fatal consequences. Advances in the 
 diagnosis and local and systemic treatment of uveal melanoma in recent times have caused a shift from enucleation to 
 eye-conserving treatment modalities. Currently, radiotherapy is the most commonly used therapeutic option, which can 
include: brachytherapy- radioactive plaque, as the most frequently used form, than stereotactic external beam radiotherapy-
radiosurgery as well as proton therapy, as a form of charged-particle radiotherapy. However, surgery as an inevitable 
therapeutic option has to be performed in some cases. In the treatment of primary tumor, local treatment methods are eff ec-
tive in preventing local recurrence in over 95% of cases. However, metastatic disease develops in up to 50% of patients, with 
liver metastases, as the most common. At this stage of the disease there is a poor survival rate of the patients (4-15 months) 
and this has remained relatively unchanged over the past decades. Although potential therapeutic targets have been identi-
fi ed, there is no currently eff ective treatment of metastatic disease. Pending clinical trials involving chemotherapeutic, 
 immunotherapeutic and molecularly targeted agents off er hope for successful tumor control and vision preservation as well 
as metastases prevention and improvement of overall patient survival.
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MELANOM SREDNJE OČNE OVOJNICE: LIJEČENJE I PROGNOZA
Sažetak
Melanom srednje očne ovojnice predstavlja 5% svih melanoma. Oko je, nakon kože, drugo primarno sijelo melanoma. 
Kasna ili kriva dijagnoza može imati ozbiljne posljedice. Napredak u dijagnostici te lokalnom i sustavnom liječenju doveo 
je do češće primjene metoda kojima je cilj očuvati oko i vid. Radioterapija, kao danas najčešći oblik liječenja, može biti pri-
mjenjena kao: brahiterapija - radioaktivni plak, najčešće korištena metoda, potom stereotaktička radioterapija vanjskim 
zračenjem, tz v. radiokirurgija, kao i čestično zračenje, npr. protonska radioterapija. Enukleacija oka se, kao neizbježni oblik 
liječenja, ipak mora primijeniti u određenim slučajevima. Kod primarnog tumora, lokalne metode liječenja učinkovite su u 
sprječavanju lokalnog recidiva u više od 95% slučajeva. Međutim, metastatska bolest razvija se u oko 50% bolesnika, a naj-
češće sijelo presadnica je jetra. Stopa preživljenja bolesnika s presadnicama je 4-15 mjeseci i gotovo je nepromijenjena tije-
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kom posljednjih desetljeća. Iako se otkrivaju potencijalne ciljne mete sistemske terapije, ne postoji još djelotvorna metoda 
liječenja metastatske bolesti. U tijeku su klinička ispitivanja liječenja kemoterapijom i imunoterapijom koja otvaraju moguć-
nosti uspješne kontrole i liječenja tumora uz očuvanja vida bolesnika te prevencije razvoja metastatske bolesti i povećanja 
stope preživljenja bolesnika.
KLJUČNE RIJEČI: melanom srednje očne ovojnice, liječenje, sustavne metastaze, prognoza
INTRODUCTION
Uveal melanoma (UM) is a rare disease ac-
counting for 0.1% of all cancer deaths. It can occur 
in all parts of the uvea: choroid (90%) (Figure 1.), 
ciliary body (7%) and iris (2%). This disease repre-
sents 80% of ocular and 5% of all melanomas (1-8). 
Over the years, with advances in treatment strate-
gies, there is an improvement in local tumor con-
trol. However the median survival rate of patients 
remains practically unchanged (2-4,7,8). Although 
rare, uveal melanoma is the most common prima-
ry intraocular malignant tumor in adults, with an 
annual incidence of fi ve to six cases per million in 
white populations in the United States and Eu-
rope (1,2). In Europe incidence of uveal melanoma 
is higher in northern (over 8 per million) com-
pared to southern countries (less than 2 per mil-
lion) indicating an association with geographic 
latitude (6). Known predisposing factors for this 
tumor are ethnicity (7), age (6,7), light eye colour, 
fair skin, the inability to tan, cutaneous, iris and 
choroidal nevus, ocular or oculodermal melano-
cytosis and familial uveal melanoma (2,4).
Uveal melanoma has a high predisposition to 
metastasize mostly in the liver (89%), lungs (29%), 
and bones (17%) resulting in a high mortality rate 
(7,9-13). Approximately, in 50% of patients with 
uveal melanoma metastasis occurs within 10 years 
of diagnosis, in spite of the treatment method 
(7,10-13). Survival rate after the onset of metasta-
sis 4-15 months (9,11) with a slightly bett er prog-
nosis in those patients receiving treatment for me-
tastasis (9,14,15).
Various clinical, histopathological, and cyto-
genetic features of uveal melanoma can identify 
patients with a high propensity for developing 
metastasis and potential benefi t of suitable adju-
vant and adjunctive treatments (Table 1). Unfortu-
nately, systemic chemotherapy is usually ineff ec-
tive in metastatic uveal melanoma resulting in a 
response rate ranging from 5% to 15% (14). De-
spite numerous therapies being developed, the 
5-year survival rate of patients with uveal mela-
noma has not improved over the past decades 
(13,14). However, participating in available clini-
cal trials with immunotherapy and targeted thera-
py remains for now the best treatment option for 
these patients (12-14).
Figure 1. Choroidal melanoma
Table 1.
RISK FACTORS FOR METASTASIS OF UVEAL MELANOMA 
Risk factors
Clinical increasing age, large tumor size, tumor 
growth, greatest basal dimension, 
oculodermal melanocytosis, ciliary body 
tumor, dark pigmented tumor,
subretinal fl uid or intraocular haemorrhage, 
extraocular extension
Histopathological epitheloid cell type, anterior location, diffuse 
growth pattern, mitotic fi gures, 
pigmentation, expressed necrosis and 
infl ammatory components
Molecular Tyrosinase m-RNA, Vascular endothelial 
growth factor,
Hepatocyte growth factor Insuline-like 
growth factor-1
Cytological Chromosome alternations (monosomy 3, 
gains in chromosome 8)





The currently accepted form of uveal mela-
noma management requires accurate evaluation 
of all prognostic factors. Applied therapy needs to 
be individualized according to various factors, 
such as patient’s age, tumor size and location, 
general health, status of the other eye as well as 
patients’ preferences and expectations. The treat-
ment modality also includes assessment for me-
tastasis risk, the planning of adjuvant therapies, 
post-treatment monitoring and control of possible 
recurrence and potential treatment-related ocular 
side eff ects. However, none of the off ered modali-
ties have improved patients’ survival (16-18).
Eye-conserving therapies and enucleation 
are possible treatment alternatives for uveal mela-
noma patients without systemic disease. Studies 
have shown that despite developments in various 
treatment procedures over the last 30 years, sur-
vival rates have remained constant indicating that 
successful local treatment of the eye does not in-
fl uence survival. Therefore, it is essential to iden-
tify patients with higher risk of metastasis and in 
addition to local treatment initiate appropriate ad-
juvant therapies. At the time of initial ocular pre-
sentation the occurrence of distant metastases is 
rare, fi nding in less than 5% of cases. In its pres-
ence, local eye therapy may be delayed in favour 
of systemic treatment depending on eye related 
symptoms (17-21).
Primary treatment
In the case of small, pigmented choroidal tu-
mor monitoring the lesion is usually adopted until 
fi ndings on colour fundus photography indicate 
growth. Since it is not possible to recognise the 
point at which tumors will metastase, the meta-
static spread may occur if treatment is delayed. 
Table 2.






≤ 18 mm in basal diameter
≤ 12 mm in thickens 
Loss of vision
Tumor recurrence
Radiation related complication (Retinopathy, 
optic neuropathy, NVG, cataract)
Proton beam 
radiotherapy
Medium to large uveal melanoma which cannot 



















Photodinamic therapy Small melanoma Tumor recurrence 
Surgery Exoresection 
+/- brachytherapy




Loss of the eye
Tumor recurrence
Risk of orbital dissemination of the tumor 
Endoresection 
+/- radiotherapy 
Small to medium sized uveal melanoma
Toxic tumor syndrome post PBR
Transient intraocular haemorrhage
Tumor seeding – rarely 
Enucleatio Large uveal melanoma (in patients with one 
seeing eye)
Melanoma associated with NVG +/- extensive 
retinal detachment
Invasion of the optic disc
Socket related complications
Orbital recurrence 
Exenteratio Large extraocular extension of uveal melanoma
Orbital recurrence after enucleation
Orbital recurrence
NVG - Neovascular glaucoma
PBR - Proton beam radiotherapy
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Conversely, small tumors should be evaluated 
considering that 30-40% of small melanomas are 
situated close to the optic disc and macula and 
treatment of all suspicious choroidal tumors in 
some cases could result in avoidable visual im-
pairment (2,22,23). Treatment of the primary tu-
mor is guided by tumor size, lesion location, gen-
eral health of the patient, visual acuity at presenta-
tion and patient preference and expectations. In 
management of uveal melanoma the assessment 
of prognostic factors should also be included. The 
main treatment options for uveal melanoma are 
eye-conserving therapies or enucleation. Studies 
have demonstrated that despite developments in 
treatment methods and the increasing tendency 
toward eye-sparing therapies, survival rates have 
remained constant (2-4,7,8,20) (Table 2).
Radiotherapy
Currently the most common treatment for 
uveal melanoma is radiotherapy which can be ad-
ministered in the form of radioactive plaque 
(brachytherapy), or with external beam radiother-
apy using stereotactic methods, radiosurgery 
(SRT), or radiotherapy with charged praticles such 
as protones (2-4,20).
Brachytherapy is the direct irradiation of a 
tumor via the application of a radioactive source 
(radioisotope) to the tumor surface or interior (2) 
(Figure 2). This type of treatment is applicable 
when melanoma is ≤ 18 mm in diameter and ≤ 12 
mm in thickness (19). The two most common ra-
dioisotopes used in the plaques are iodine-125 
(125I) and ruthenium-106 (106Ru) (19,24). 125I plaques 
emit gamma radiation, which has a deeper pene-
tration than the beta-emitt ing 106Ru but increased 
toxicity to surrounding healthy tissue (8,24). The 
lower penetration depth of 106Ru makes it unsuit-
able for thick tumors and is generally restricted to 
those that are less than 6 mm in thickness (8,25). 
Regular ophthalmologic examinations should be 
performed following plaque brachytherapy to as-
sess for radiation-induced damage, including ra-
diation retinopathy, papillopathy, exudative reti-
nal detachment and cataract which can develop 2 
to 5 years following initial treatment (8).
External beam radiotherapy can be per-
formed using diff erent stereotactic methods or 
charged particles such as proton and helium ion 
beams. This modality can be used to treat tumors 
up to 14 mm thick with a basal diameter up to 28 
mm (2,8,26).
Proton beam therapy is a form of radiation 
treatment which emits homogenous dose of radia-
tion to the entire tumor while limiting irradiation 
of surrounding tissues (2,27). Theoretically, all 
uveal melanomas could be treated by proton beam 
therapy but for large melanomas the visual prog-
nosis and eye conservation rates remain low 
(27,28). The fi rst choice of treatment for large tu-
mors located in the superotemporal quadrant 
should be radioactive plaque radiotherapy in or-
der to spare the lacrimal glands. Possible compli-
cations of proton beam therapy are loss of eye-
lashes, retinal detachment, glaucoma, dry eye, 
cataract, optic neuropathy and maculopathy.
Transpupillary thermotherapy (TTT) was 
used as an adjuvant therapy when the tumor was 
close to the macula or to decrease the likelihood of 
neovascular glaucoma and recurrence was not ob-
served in these patients (2,19,28).
The devices used in stereotactic radiotherapy 
(SRT) are the gamma knife, linear accelerator and 
the cyber knife. Ocular immobilization is required 
during these treatments. This can be achieved 
with retrobulbar anaesthesia or vacuum-assisted 
immobilization frame for the gamma knife and 
the cameras used to monitor eye movements for 
the linear accelerator (28). The local tumor control, 




visual acuity and survival rate with this method is 
similar to the proton beam therapy (2,19).
Photocoagulation, transpupillary thermal therapy 
and photodynamic therapy
Photocoagulation was frequently used in the 
past to treat small choroidal melanoma. Today, 
small tumors less than 3 mm in thickness and lo-
cated more than 3 mm from the fovea are treated 
with TTT (2,29) (Figure 3). Patients undergoing 
TTT alone for uveal melanoma should be selected 
carefully keeping in mind that although visual 
prognosis is good, there remains the long-term 
possibility of recurrence with high metastatic risk 
(2). Several studies have explored the potential 
role of TTT in combination with brachytherapy 
(“sandwich therapy”) and proton beam therapy, 
with mixed results (8,30). TTT has also been used 
as an adjuvant therapy, although no improved lo-
cal control was observed in 125I-treated juxtapapil-
lary uveal melanoma (8).
Complications of radiotherapy
Complications of radiation treatment of uve-
al melanoma can be radiation retinopathy and ra-
diation induced optic neuropathy.
Radiation retinopathy is a slowly progressive 
disease caused by radiation-induced endothelial 
damage and capillary occlusion which results in 
retinal haemorrhage, macular oedema, vascular 
sheathing, microaneurysms, retinal exudation, 
telangiectasias, retinal pigment epithelial atrophy 
and cott on wool spots. Retinopathy occurrence is 
dependent on the total radiotherapy dose received 
and the area of the retina irradiated. Ischemic reti-
nopathy can often progress to proliferative reti-
nopathy with possible vitreous haemorrhage 
(2,3,31). Treatment options include panretinal or 
focal laser photocoagulation, photodynamic ther-
apy, intravitreal or periocular triamcinolone injec-
tion, oral pentoxifylline, hyperbaric oxygen, intra-
vitreal anti-vascular endothelial growth factor 
(anti-VEGF) and silicone application prior to 
brachytherapy (2,3,31).
Radiation-induced optic neuropathyis char-
acterized by optic disc haemorrhage, disc pallor, 
and/or disc oedema. It is manifested with sudden, 
painless, unilateral vision loss starting as early as 
3 months or up to 8 years after radiation exposure 
(2,3,31). There is no proven treatment of radiation 
optic neuropathy; mixed results have been report-
ed for systemic and intravitreal corticosteroids or 
intravitreal anti-VEGF therapy, hyperbaric oxy-
gen and anticoagulation therapy (2,3,31).
Surgery - enucleation, exenteration, 
local resection
Although enucleation was formerly the most 
common treatment choice, it is currently reserved 
for cases with the worst visual prognosis, such as 
patients with large uveal melanoma (tumoral 
thickness greater than 8 mm), choroidal melano-
ma surrounding the optic nerve or presenting 
with retinal detachment or vitreous haemorrhage. 
There is no consensus on the maximum tumor 
thickness that can be treated by radiotherapy (2-
4,8,19). In response to the results of Collaborative 
ocular melanoma study (COMS) in which enucle-
ation did not provide any survival benefi t over 
brachytherapy in medium-sized choroidal tu-
mors, vision-sparing treatments become the pre-
ferred choice (10). Furthermore pre-enucleation 
Figure 3. Choroidal melanoma – fi nding after transpupillary 
thermotherapy
Photodynamic therapy involves injection of a 
light-sensitive compound, such as benzoporphy-
rin or verteporfi n, followed by exposure to a spe-
cifi c wavelength of light in order to release dam-
aging free radicals that can destroy neighbouring 
vascular endothelial cells. The long-term local 
control and disease-free survival benefi t of this 
technique are still under investigation (19).
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radiotherapy did not seem to improve survival in 
patients with large choroidal melanomas (32). In 
eyes with large areas of extraocular extension or 
those with orbital tumor extension orbital exen-
teration is performed (2,14,16).
Local resection is an alternative treatment 
choice for choroidal melanoma patients which 
spares the eye and allows a detailed histopatho-
logic and cytogenetic analysis. The procedure is 
more preferred in cases of iris and ciliary body 
melanoma. It can be performed transretinaly (en-
doresection) or transscleraly (exoresection) with 
vitreous haemorrhage and retinal detachments 
being possible complications. Radiotherapy is rec-
ommended as an adjuvant to exoresection to pre-
vent tumor recurrence although its preventative 
application before endoresection is still controver-
sial (2,33).
Systemic metastasis
At the time of diagnosis, less than 5% of pa-
tients with uveal melanoma have detectable meta-
static disease. However, with the tumor progres-
sion nearly half of the patients will develop metas-
tases (2-4,20,21) (Table 3). Once metastasis has 
occurred survival is poor due to the lack of eff ec-
tive systemic treatment. Uveal melanoma dissem-
inates hematogenously, with the most common 
metastatic sites in liver, lung and bones (34,35), 
but metastases in the brain, skin and other sites of 
the body can be also found (43). Patients with liver 
metastases survive for an average of 4-6 months 
with a 1-year survival rate of 10-15%. Reported 
survival time for patients with other metastases is 
19-28 months (2,4,35) (Table 4).
There are no defi nitive guidelines regarding 
screening tests for systemic metastasis in uveal 
melanoma however clinical examination for the 
presence of subcutaneous nodules and organo-
megaly is the basis. Since the most frequent site of 
metastasis is the liver, examination should include 
liver function tests and complementary radiogra-
phy methods particularly ultrasonography (USG) 
(2-4,21,36). The most sensitive method for liver 
imaging is contrast and magnetic resonance imag-
ing (MRI). Computed tomography (CT) is highly 
sensitive yet its ability to discriminate from be-
nign lesions is limited. Brain imaging and bone 
scan are required only in the presence of related 
symptoms (2,37).
Numerous clinical and histopathological fea-
tures have been investigated in order to predict 
prognosis of uveal melanoma. Factors associated 
with poor outcome include advanced patient age 
at time of diagnosis, large tumor size, extrascleral 
extension of the tumor, involvement of the ciliary 
body and presence of subretinal fl uid or intraocu-
lar hemorrhage. Certain pathologic features in-
cluding epithelioid cytology, increased mitotic 
activity, extracellular matrix patt erns, immune 
cell infi ltration and incomplete local control after 
primary tumor treatment are also connected with 
poor prognosis (2-4,8,11,38).
Adjuvant therapy
Local treatment of a primary uveal tumor is 
eff ective in preventing local recurrence in over 
95% of cases; nevertheless nearly 50% of patients 
will develop metastatic disease in a median time 
of 5 years. In fact, circulating uveal tumor cells 
have been detected at diagnosis in patients with 
no detectable metastases (8,39). Metastatic uveal 
melanoma is resistant to treatment with no evi-
dence that current treatment can extend survival. 
The effi  cacy of systemic treatment could be im-
proved with adjuvant therapies that target micro-
metastases and the identifi cation of patients at 
high risk is very important. There is currently no 
standard therapy for metastatic uveal melanoma 
with a broad range of systemic treatment options 
Table 4.
SITES OF SYSTEMIC METASTASIS OF UVEAL MELANOMA
Site of systemic 
metastasis Incidence (%)






Lymph nodes 11 19-28
Table 3.
SYSTEMIC METASTASIS OF UVEAL MELANOMA IN 
RELATIONSHIP TO THE SITE OF THE PRIMARY TUMOR
Site of primary tumor Systemic metastasis incidence (%)
3 years 5 years 10 years
Iris 0.5 4 7
Ciliary body 12 19 33
Choroidal 8 15 25
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including chemotherapy, immunotherapy, hor-
mone, biologic and targeted therapy. Hepatic-di-
rected treatments have also been developed; how-
ever intra-arterial hepatic administration result in 
bett er tumor response than systemic therapy 
without increasing survival in the long term 
(8,25,40).
Treatment of metastatic uveal melanoma
Systemic chemotherapy
Systemic chemotherapeutic protocols in uve-
al melanoma have been adopted from those used 
in cutaneous melanoma however no conventional 
chemotherapeutic agent has been found to extend 
survival in patients with metastatic disease. Re-
sponse rates for systemic chemotherapy of meta-
static uveal melanoma range from 0% to 15% (2-
4,8,19).
Systemic immunotherapy
Recent advances in immunotherapy have 
considerably improved survival of patients with 
metastatic cutaneous melanoma although the clin-
ical benefi t in uveal melanoma is more limited. A 
possible explanation is that uveal melanoma is 
typifi ed by a low mutational burden, since UV ra-
diation–induced DNA damage does not play a 
signifi cant role in tumor pathogenesis (8,41). An-
other possible explanation arises from “immune 
privilege” of the eye, meaning an adaptation to 
reduce immune-mediated injury in organs that 
have limited capacity for regeneration such as the 
eye and brain. Studies have shown that aqueous 
humour contains a number of anti-infl ammatory 
and immunosuppressive cytokines (8,42) which at 
least partially could be an explanation for this im-
munological adaptation.
Molecularly targeted therapy
As a result of increased understanding of the 
oncogenic pathways in uveal melanoma a number 
of potential therapeutic targets have been recog-
nized. Since the mitogen-activated protein kinase 
(MAPK) pathway is activated in the majority of 
uveal melanoma cases, inhibitors of downstream 
eff ectors, for instance mitogen activated kinase 
(MEK) and protein kinase C (PKC) are presently 
undergoing clinical investigation. The common 
BRAF mutations in cutaneous melanoma are pres-
ent in less than 1% of uveal melanoma tumors. 
Thus BRAF inhibitors become unsuitable for treat-
ing uveal melanoma even though they have prov-
en to be benefi cial in the treatment of the cutane-
ous tumor type (8).
Liver-directed therapies
In certain cases, surgical removal of metastat-
ic nodules can off er long-term survival benefi t. Al-
ternative approaches include radiofrequency ab-
lation, cryotherapy and stereotactic radiotherapy. 
Other liver-directed therapies take advantage of 
the dual blood supply in the liver which allows 
more direct treatment of the metastases via the he-
patic artery. Hepatic artery branches vascularize 
the melanoma, whereas the portal circulation de-
livers the majority of blood to the normal liver tis-
sue. Intrahepatic therapeutic methods consist of 
bland embolization, intra-arterial administration 
of chemotherapies, isolated hepatic perfusion, in-
tra-arterial hepatic chemo embolization, radioem-
bolisation and immune embolization (8,19,43) 
(Table 5).
Prognostic and predictive factors
The patients treated with plaque brachyther-
apy, proton beam radiotherapy or stereotactic ra-
diotherapy should be closely monitored for tumor 
regression during the fi rst two years after primary 
treatment (16). Further follow up is dependent on 
the tumor response to brachytherapy and possible 
radiotherapy complications.
Regular screening is recommended for pa-
tients at high risk of relapse. This screening in-
cludes hepatic imaging (CT/MRI) and liver func-
tion tests conducted in a three to six month inter-
val for the fi rst fi ve years followed by six to twelve 
month intervals thereafter. Although surveillance 
regimens diff er, some studies suggest lactate dehy-
drogenase (LDH) and gamma-glutamyl transferase 
(GGT) as the most sensitive liver function tests for 
uveal melanoma which are most often elevated 
with advanced hepatic involvement (17,44).
Future Directions
Advancement of the understanding of bio-
logical behaviour of the uveal melanoma is central 
to the development of new therapeutic strategies. 
Programs addressing genomic alterations of pri-
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mary or metastatic cutaneous melanoma and ge-
nomic analysis of uveal melanoma is currently be-
ing undertaken (8,45). The results of this analysis 
will potentially lead to the identifi cation of new 
therapeutic targets and the development of new 
treatment methods for this rare subtype of mela-
noma (8). Currently, immunotherapy in uveal 
melanoma represents an area of active investiga-
tion (46). While inhibition with anti-programmed 
death protein-1 (anti–PD-1) and anti-cytotoxic T-
lymphocyte-associated protein 4 (anti–CTLA-4) 
therapy has considerably altered the treatment 
approach to cutaneous melanoma, its eff ective-
ness for uveal melanoma is still being assessed 
(2,8,19,43,46).
CONCLUSION
Uveal melanoma is a rare but fatal disease 
whose biological behaviour is notably diff erent 
from other forms of melanoma and therefore re-
quires distinct treatment strategies. It is a complex 
malignancy requiring expertise in its management 
and despite all measures being taken has a high 
tendency for poor prognosis in the future. Even 
though no standardized treatment for metastatic 
uveal melanoma exists, considerable progress has 
been made to bett er our understanding of the biol-
ogy of this melanoma type, leading to novel tar-
geted therapy and immunotherapy approaches. 
Recent improvements in prognostic and diagnos-
Table 5.
LIVER DIRECTED THERAPY METHODS USED IN THE TREATMENT OF UVEAL MELANOMA METASTASIS
Procedures Comments Outcome
Hepatic metastasectomy • Surgical resection
• Limited indication (good physical condition 
for general anesthesia)
• Small number of potential candidates 
(<10% patients with liver uveal metastasis) 
• Median OS time >12 months
• Has not enhanced survival in comparison to 
systemic therapy
• Common local relapse 
Radiofrequency ablation • Method that spares the hepatic parenchyma
• Anesthesia and extensive surgical procedure 
are avoided
• Minimal morbidity and mortality
• No difference in survival time and DFS 
in regard to surgical resection 
Hepatic arterial infusion of 
chemotherapy 
• Anatomic option for patients with liver predominant 
disease
• Applicable since metastatic tumors are predominantly 
supplied by the hepatic artery
• Signifi cantly improved PFS compared to 
intravenous administration of chemotherapy
• No improvement in OS
Isolated hepatic perfusion 
(IHP) 
• Delivers high doses of chemotherapy to the liver 
with minimum systemic drug exposure
• Requires great skill and extracorporeal circulation 
(limited use)
• Radiological response in 68% of the 
patients, with 12% having a complete 
response
• Time to local progression was 7 months
• Median OS time up to 24 months
Percutaneous hepatic 
perfusion (PHP)
• Similar procedure to IHP
• Simpler to perform 
• Signifi cantly improved median PFS 
compared with best supportive care
• No improvement in OS
Chemoembolization • Combines hepatic artery embolization with infusion 
of chemotherapeutic agents
• Patients with low tumor burden (<20% liver 
involvement ) – signifi cantly improved OS
• Patients with high tumor burden (< 75% 
liver involvement ) – poor clinical response 
and numerous major complications
Immunoembolization • Use of GM-CFS
• Increase local mobilization and maturation of dendritic 
cells to the tumor area after ischemic necrosis 
of the tumor as a consequence of embolization
• Median PFS shorter than in the group 
with only embolization applied 
Radioembolization • Liver directed approach using yttrium-90 (90Y) 
radiospheres
• Passes deep into tumor vessels
• Cannot enter the capillaries (sparing normal liver tissue 
surrounding the tumor )
• High response rates (up to 62% patient 
with defi ciency being small sample size)
• Median OS 7 to 10 months 




tic methods have not improved outcomes for uve-
al melanoma. The search for eff ective targeted 
therapy as well as eff ective immunotherapy for 
metastatic disease is still in progress. Additional 
studies are necessary to comprehend and enhance 
the effi  cacy of targeted therapy and immunother-
apy in ocular melanoma. Decisions regarding 
treatment and the best clinical approach are im-
perative in order to provide individualized pa-
tient care.
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